Compare WABC & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WABC | CRVS |
|---|---|---|
| Founded | 1972 | 2014 |
| Country | United States | United States |
| Employees | 627 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 1994 | 2016 |
| Metric | WABC | CRVS |
|---|---|---|
| Price | $55.81 | $11.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $54.00 | $30.17 |
| AVG Volume (30 Days) | 131.9K | ★ 1.6M |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ 3.40 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.93 | $3.55 |
| 52 Week High | $56.36 | $26.95 |
| Indicator | WABC | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 61.05 | 35.33 |
| Support Level | $46.73 | $11.42 |
| Resistance Level | $56.11 | $19.21 |
| Average True Range (ATR) | 1.02 | 0.97 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 81.03 | 4.66 |
Westamerica Bancorp provides a full range of banking services to individual and commercial customers in Northern and Central California through its subsidiary bank. The Bank is a California-chartered commercial bank whose deposits are insured by the Federal Deposit Insurance Corporation (the FDIC) up to applicable limits. The principal communities served are located in Northern and Central California, from Mendocino, Lake and Nevada Counties in the north to Kern County in the south. The Company's strategic focus is on the banking needs of small businesses.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.